Tesamorelin vs Sermorelin vs Ipamorelin: How the Growth Hormone Peptides Differ

If you have been researching growth hormone peptides, you have run into the same three names — sermorelin, ipamorelin and tesamorelin — usually alongside a confident claim about which one is better, and almost never alongside a citation. This article does the opposite.

The short version. Sermorelin and tesamorelin are analogs of growth hormone-releasing hormone (GHRH) and signal through the GHRH receptor. Ipamorelin signals somewhere else entirely — through the growth hormone secretagogue receptor, the same receptor the body's own hormone ghrelin uses. That single distinction, not any ranking, is what separates these molecules. Their research bases are also not comparable in size, and were built in different study populations.

The One Difference That Explains All the Others

The pituitary somatotroph — the cell that releases growth hormone — can be signaled through two separate receptors, and those receptors use two separate internal messaging systems.

A 2002 review in Current Drug Targets: Immune, Endocrine and Metabolic Disorders describes both. GHRH acts through a G-protein coupled receptor that activates adenylyl cyclase, cyclic AMP and the protein kinase A pathway. Ghrelin — the body's endogenous growth hormone secretagogue, a product of the oxyntic cells in the stomach — acts through a different G-protein coupled receptor that stimulates phospholipase C, leading to production of inositol 1,4,5-trisphosphate and diacylglycerol, an increase in cytosolic calcium, and growth hormone release. The same review reports that ghrelin and GHRH act synergistically when administered together in vivo, but only additively when incubated with somatotrophs in vitro (Root and Root, Curr Drug Targets Immune Endocr Metabol Disord, 2002, PMID 12477295).

Sermorelin and tesamorelin sit on the first pathway. Ipamorelin sits on the second. Almost every other difference between these three molecules follows from that one fact.

Tesamorelin vs Sermorelin: Two GHRH Analogs, Two Different Research Bases

Both molecules are built from GHRH, so start with the parent hormone. A review in Clinics in Endocrinology and Metabolism describes human GHRH as a 44-residue amidated peptide, or its C-terminal-shortened derivatives — sermorelin corresponds to the 1-29 fragment. The same review reports that pulsatile growth hormone release is principally a consequence of the pulsatile release of hypothalamic GHRH; that in normal adults several analogs of GHRH were shown to be sensitive and specific stimuli to growth hormone release, with a variable prolactin response usually of small magnitude; and that continuous infusion of GHRH leads to a decrement in responsiveness, attributed at least in part to changes in hypothalamic somatostatin (Grossman et al., Clin Endocrinol Metab, 1986, DOI).

That last point matters when reading peptide marketing. The same review notes the growth hormone response to GHRH is modulated by obesity, blood sugar, free fatty acids, and growth hormone itself — meaning the response to a GHRH analog is not a fixed quantity, and metabolic context changes it.

Tesamorelin is where the two diverge sharply, because tesamorelin has large randomized human trials behind it and sermorelin does not have an equivalent modern body. A 2012 paper in Clinical Infectious Diseases reports that tesamorelin, a GHRH analog, decreases visceral adipose tissue by 15 to 20 percent over 6 to 12 months in individuals with HIV-associated abdominal adiposity. That paper analyzed 402 subjects initially randomized to tesamorelin across two phase III randomized, double-blind studies. Subjects with at least an 8 percent reduction in visceral adipose tissue were defined in advance as responders; compared with nonresponders, responders showed greater mean reduction in triglycerides at 52 weeks (-0.8 mmol/L versus 0.0 mmol/L, p = .003) and attenuated changes in hemoglobin A1c at 52 weeks (0.0 percent versus 0.2 percent, p = .003) (Stanley et al., Clin Infect Dis, 2012, DOI).

Two things about those figures. They were generated in a specific clinical population — people with HIV-associated lipodystrophy — and they do not automatically transfer to anyone else. And a 2010 review in Current Opinion in Investigational Drugs, written while those trials were reporting, noted that additional long-term outcome trials were required to determine the long-term safety of tesamorelin and to evaluate whether it or other growth hormone-releasing factor agonists could reduce cardiovascular risk (Hu and Tomlinson, Curr Opin Investig Drugs, 2010, PMID 20872317). That is a limitation worth carrying into any conversation about this molecule.

Sermorelin vs Ipamorelin: A Different Receptor and a Different Selectivity Profile

Ipamorelin was introduced in European Journal of Endocrinology in 1998 as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2). Pharmacological profiling using GHRP and GHRH antagonists demonstrated that ipamorelin stimulates growth hormone release via a GHRP-like receptor rather than the GHRH receptor.

The finding that paper emphasized concerns selectivity. In conscious swine, administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol. Ipamorelin did not release ACTH or cortisol at levels significantly different from those seen after GHRH stimulation — and that held even at doses more than 200-fold higher than the ED50 for growth hormone release. None of the secretagogues tested affected FSH, LH, prolactin or TSH plasma levels in swine. The authors concluded that ipamorelin was the first GHRP-receptor agonist with a selectivity for growth hormone release similar to that displayed by GHRH (Raun et al., Eur J Endocrinol, 1998, DOI).

This is the single most-cited fact about ipamorelin, and it is important to read it precisely: it is animal data — rat pituitary cells, anaesthetized rats and conscious swine — from a pharmacology paper, not a human clinical outcome trial.

Ipamorelin vs Tesamorelin: Comparing Across Categories

People search this pairing frequently, but it is a comparison across two different categories of evidence rather than a head-to-head. Tesamorelin has phase III randomized, double-blind human trial data in a defined population (Stanley et al., Clin Infect Dis, 2012, DOI). Ipamorelin's foundational literature is preclinical pharmacology characterizing its receptor and its selectivity (Raun et al., Eur J Endocrinol, 1998, DOI), with later work exploring the ghrelin receptor in other contexts entirely, such as a rodent model of postoperative ileus (Venkova et al., J Pharmacol Exp Ther, 2009, DOI).

We could not locate a published randomized head-to-head trial comparing ipamorelin with tesamorelin. Any source that presents one should be read carefully.

Sermorelin vs CJC-1295: A Question of How Long the Molecule Persists

CJC-1295 appears constantly in this comparison. What is documented about it is structural. A 2018 paper in Drug Testing and Analysis describes CJC-1295 as a 30 amino acid peptide-based drug that stimulates the release of growth hormone from the pituitary gland, and describes it as unique among performance-enhancing peptides because of a reactive maleimidopropionic acid group that covalently links the peptide to free thiols on the surface of plasma proteins. Once conjugated, the paper notes, CJC-1295 remains active in the bloodstream significantly longer than non-conjugated peptide-based drugs, which are rapidly excreted (Timms et al., Drug Test Anal, 2018, DOI).

Read that alongside the Grossman observation that continuous GHRH exposure produced a decrement in responsiveness, and you can see why duration of action is the interesting variable in the sermorelin and CJC-1295 comparison rather than potency. We did not find published clinical outcome trials comparing the two directly, and so we are not presenting one.

Sermorelin vs HGH: Stimulating the Pituitary or Supplying the Hormone

This is a category difference rather than a dose difference. Recombinant human growth hormone supplies the hormone itself. GHRH analogs and secretagogues act upstream, prompting the pituitary to release its own.

The 2002 Root and Root review states directly that GHRH enhances linear growth rate in children with growth hormone deficiency but is less effective than recombinant human growth hormone in doing so, and that peptidyl and non-peptidyl growth hormone secretagogues have been used in diagnostic studies for growth hormone deficiency and in treatment of small groups of subjects (Root and Root, Curr Drug Targets Immune Endocr Metabol Disord, 2002, PMID 12477295). The 2010 review similarly notes that growth hormone-releasing factor analogs with greater stability than the natural hormone can induce growth hormone secretion in a physiological manner (Hu and Tomlinson, Curr Opin Investig Drugs, 2010, PMID 20872317).

Side-by-Side: The Four Molecules People Compare

• Sermorelin — corresponds to the 1-29 fragment of GHRH; acts on the GHRH receptor; the parent hormone's response is modulated by obesity, blood glucose, free fatty acids and growth hormone itself (Grossman et al., 1986).
• Tesamorelin — a GHRH analog; the only one of these four with published phase III randomized double-blind trial data, generated in HIV-associated abdominal adiposity (Stanley et al., 2012).
• Ipamorelin — a pentapeptide acting on the GHRP/ghrelin receptor, characterized in animal studies as not raising ACTH or cortisol in the way GHRP-6 and GHRP-2 did (Raun et al., 1998).
• CJC-1295 — a 30 amino acid peptide documented as binding covalently to plasma proteins, which extends how long it remains active in the bloodstream (Timms et al., 2018).

What the Choice Actually Depends On

Not on which molecule ranks highest, because the literature does not support a ranking. It depends on which pathway is being addressed, how much and what kind of published evidence sits behind a given molecule, whether the population studied resembles the person asking, and what a full workup shows about the growth hormone axis and the metabolic context around it — since the GHRH response itself shifts with body composition and glucose handling (Grossman et al., 1986).

That is a clinical conversation with labs in front of you, not a decision to make from a comparison table. We publish what the evidence says; we do not publish protocols. Dosing, combinations, frequency and duration are individualized and determined in consultation, and you will not find numbers for them on this website.

Frequently Asked Questions

What is the difference between sermorelin and ipamorelin?

Receptor. Sermorelin acts on the GHRH receptor, which signals through adenylyl cyclase, cyclic AMP and protein kinase A. Ipamorelin acts on the growth hormone secretagogue receptor, which signals through phospholipase C and a rise in cytosolic calcium (Root and Root, 2002, PMID 12477295; Raun et al., 1998, DOI).

Is ipamorelin the same as sermorelin?

No. They are structurally unrelated. Sermorelin corresponds to a fragment of the 44-residue GHRH molecule; ipamorelin is a five-amino-acid peptide developed from a different chemistry program, identified within a series of compounds lacking the central dipeptide of GHRP-1 (Raun et al., 1998, DOI).

Is ipamorelin better than sermorelin, or sermorelin better than ipamorelin?

The published literature does not answer that question, because it does not contain a randomized head-to-head trial between them. What it contains is a mechanistic distinction and separate characterization studies. Anyone stating a winner is going beyond the evidence.

Can you take sermorelin and ipamorelin together?

Combination use is a common question and a clinical decision rather than an article-level one. What the literature does establish is that GHRH and ghrelin-receptor signaling interact — the 2002 review reports they act synergistically in vivo and additively in vitro (Root and Root, 2002, PMID 12477295). Whether any combination is appropriate, and in what form, is individualized and determined in consultation. We do not publish combination protocols.

What is a sermorelin ipamorelin blend?

The term refers to preparations containing more than one of these peptides. Because the composition, sourcing and clinical appropriateness of such preparations vary, this is a consultation topic rather than something to evaluate from a product description.

What is the difference between sermorelin, tesamorelin and ipamorelin?

Sermorelin and tesamorelin are both GHRH analogs acting on the same receptor, and differ mainly in the size and setting of their published evidence — tesamorelin has phase III randomized data in HIV-associated abdominal adiposity (Stanley et al., 2012, DOI). Ipamorelin acts on a different receptor entirely (Raun et al., 1998, DOI).

Do these peptides work the same way as HGH?

No. Recombinant human growth hormone supplies the hormone. These molecules act upstream on the pituitary. The 2002 review notes that GHRH is less effective than recombinant human growth hormone at enhancing linear growth rate in children with growth hormone deficiency (Root and Root, 2002, PMID 12477295).

Growth Hormone Peptide Consultations in Ann Arbor

At Arbour Longevity, peptide conversations start with labs and a full history, not with a molecule. Gandhi Bhattarai, FNP-BC, PMHNP-BC, Anti-Aging/Functional Medicine BC is a triple board certified nurse practitioner, and reviews the growth hormone axis alongside thyroid, metabolic and sex hormone markers before discussing whether peptide therapy belongs in a plan at all. If you want the background first, our guides to what peptide therapy is and BPC-157 cover the wider category, and our sermorelin service page and BPC-157 service page cover what we offer.

We are at 2217 Packard St #15, in the Eastover Professional Center, Ann Arbor, MI 48104, open Thursday through Monday, 10am to 7pm, and we see patients from across Washtenaw County. Call (734) 436-3357 or book your first visit. The first visit is $35, applied toward your treatment plan. We are cash pay and accept HSA and FSA.